Genmab — Januar 2026

[Sukkeralf]

Lyder lovende for TCE narkedet fremadrettet

[E_L]

For the Dutch : Dr. Marcel Nijland over epcoritamab met R2 bij R/R folliculair lymfoom https://www.mednet.nl/congres-nieuws/dr-marcel-nijland-over-epcoritamab-met-r2-bij-r-r-folliculair-lymfoom/

[E_L]

NASDAQ TRADE HALT OMXCOP:GMAB HALT NEWS PENDING AT 12:55 PM

[E_L]

https://ir.genmab.com/news-releases/news-release-details/genmab-announces-topline-results-epcoritamab-duobodyr-cd3xcd20 Genmab Announces Topline Results for Epcoritamab (DuoBody CD3xCD20) from Phase 3 EPCORE DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

[Sukkeralf]

Ikke godt: The study did not demonstrate a statistically significant improvement in overall survival (OS) (HR: 0.96 [95% CI 0.77 to 1.20])

[Solsen]

Det var ærgerligt. Monoterapi er ikke godt nok. Resultatet vil give lidt usikkerhed.

[E_L]

OS indeed disappoints -on the first look. we all know though during what period this trial was conducted, and analysis will have to show how disappointing it really is, or if Covid circumstances led to this result, and other therapies after controll arm relapse which could be a factor...

[E_L]

PFS was a win

[E_L]

the drop seems excessive, but i can understand it, as we don't know the exact additional circumstances

[E_L]

reality is also that mono therapy will not really matter that much going forward , me thinks...

[E_L]

ABBV hardly blinked, but it is offcourse still a small impact on Abbvie

[E_L]

it is a shame this news did not come just before JPM, Jan could have explained possibel causes a bit... we may not hear any comments on it now until Q1 in Feb?

[Solsen]

https://borsen.dk/nyheder/virksomheder/genmab-viser-igen-lovende-kraeftdata-i-nyt-studie?b_source=borsen&b_medium=row_-1&b_campaign=latest_news_1 ???

[perstu]

Både Børsen og Finans har lovende overskrifter - "Genmab viser igen lovende kræftdata..

[E_L]

Truist maintains optimism for 2026 read-out after Genmab’s Phase 3 trial OS miss https://www.tipranks.com/news/the-fly/truist-maintains-optimism-for-2026-read-out-after-genmabs-phase-3-trial-os-miss-thefly#google_vignette

[E_L]

Truist notes Genmab (GMAB) reported Phase 3 results from the EPCORE DLBCL-1 trial in transplant-ineligible second-line positive diffuse large B-cell lymphoma patients. The study missed its overall survival endpoint. However, this outcome does not change the firm’s view on the key frontline DLBCL study, and Truist remains optimistic for a positive read-out this year. The firm has a Buy rating on the shares with a price target of $48.

[JKY_VH]

Fra Børsen "Og studiet peger ifølge Genmab på en forbedring af den progressionsfri overlevelse, når Epcoritamab blev anvendt som monoterapi.

“Derudover blev der observeret forbedringer i den komplette responsrate, responsvarigheden og tiden til næste behandling blandt patienter, der blev behandlet med Epcoritamab som monoterapi,” skriver Genmab i en meddelelse.

Det er ifølge Genmab det første fase 3-studie til dato, der har vist en forbedret progressionsfri overlevelse i patienter med

[JKY_VH]

Til gengæld har Epcore DLBCL-1-studiet ikke kunnet vise en statistisk signifikant forbedring af den overordnede overlevelsesgrad.

[Solsen]

Og det er netop det ultimative endpoint. Så ikke nogen succes.

[E_L]

which is why they will need to discuss with FDA. AbbVie is an experienced partner, that may pay off now. we'll see...